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Botulinum neurotoxin type A (BoNT/A) is the
active substance in preparations used both for
cosmetic purposes and to treat a variety of neuro-
logical disorders. In somepreparations, theBoNT/A
protein form part of a multi-protein complex. Al-
though the accompanying proteins are consid-
ered to play no role in the mechanism of action,
their presence has raised concerns regarding the
amount of total protein administered, sensitiza-
tion to the preparation, and the formation of neuro-
toxin neutralizing antibodies leading to therapeutic
failure. Preparations that contain only the BoNT/
A protein could potentially limit the development
of such an immune response. Hence, it is impor-
tant to knowhowmuchBoNT/Aprotein is present.
The article by Dr Ju¨rgen Frevert published in
this issue of Drugs in R&D[1] describes the evalu-
ation of the BoNT/A concentration in three for-
mulations of licensed therapeutic preparations
using a sensitive sandwich ELISA assay developed
in-house. Only Xeomin/Bocouture contains pure
BoNT/A protein and is claimed to have the highest
purity and specific activity of the formulations
tested.
The study is relevant for the characterization
of therapeutic preparations of botulinum toxin
but is potentially controversial. It is therefore essen-
tial that the information presented is correct and
is adequately scrutinized. The conclusions of the
paper appear to be based on rather limited and
variable data, particularly for products other
than Xeomin, and should ideally be supported
by more focused experimental studies. The claim
that the new immunoassay is able to detect only
neurotoxin is potentially speculative. It is claimed
that antibodies have no ability to detect addi-
tional complexing proteins/other clostridial pro-
teins that are known to be present in products
other than Xeomin but no direct evidence of this
specificity is directly presented in this paper.
The main argument is that not all toxin A pro-
ducts are of the same purity and that a particular
brand may be of lowest specific activity, despite
the authors own claim of no difference in clinical
use and in laboratory mouse bioassays studies.
This assertion is not entirely novel as a previous
paper by Ekong et al.[2] reached the same conclu-
sion for the licensed therapeutic toxin A products
at that time. The conclusion then was based on
the observation of differences in the ratio of im-
munodetected toxin to their biological activity.
The capture antibody ELISA methodology de-
scribed in the 1995 paper is virtually identical to
the method published here. Although particular
product brands were not specifically identified in
the previous publication, those familiar with these
products would have been able to calculate that
for Dysport, the toxin A content was approx-
imately 2.0 ng/500 dose that is lethal to 50% of
animals tested (LD50) [0.4 ng/100 LD50], which is
lower than the content claimed for this brand and
slightly lower than, although comparable to, the
value reported by Dr Frevert.[1] It is highly likely
that further values will be calculated in other labo-
ratories as the results are both method and reagent
specific. It may not be possible to be certain that a
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value determined by Dr Frevert is ‘true’ until it is
verified in another laboratory. Furthermore, un-
like the previously published study, the biologic
activity was not determined by direct comparison
but used information provided by the manu-
facturer. It is not possible to calculate the specific
purity of toxin A in proprietary products from
LD50 values provided by the individual manu-
facturers, unless these values are normalized or
standardized. Dr Frevert’s conclusions are con-
sistent with other publications on this subject[3-5]
that agree the LD50 values indicated on product
labels cannot be standardized due to in-house
differences in LD50 protocols, which result in
differences in the potency and hence bias the
calculation of specific activity.
Despite these limitations the sandwich ELISA
assay is arguably the best available for the detection
of toxin but the suitability of this particular version
should be confirmed by other laboratories. In addi-
tion, estimation of toxin content in other prepara-
tions, including pure neurotoxin formulations, such
as in samples reported by Sesardic et al.,[5] would be
useful, as loss of activity during the production
process has been confirmed in bioassays.
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